Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

Roscommon's Simon Walker overcame a windchill factor of minus two and rainswept winds gusting to 50km/h to grab the first-round lead in the Connolly Motor Group-sponsored West of Ireland ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Simon Walker looks to have found a perfect contender for the Amateur Derby at Epsom in Beauld As Brass after the five-year-old completed a quick-fire hat-trick with ease. The winner was once again ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. The drugmaker Pfizer is ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug. (Image Credits: Reuters) Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...